Search

everythinglearnresearchcommunity

for

Search:↓

A user shared their hair loss journey, starting treatments with topical minoxidil and finasteride at 17, and later adding oral versions and dutasteride by age 20, but still experiencing hair loss. Others suggested that the treatments have likely slowed the progression, and some recommended considering a hair transplant or adjusting medication, while expressing concerns about the potential side effects of starting such treatments at a young age.

A 20-year-old FTM individual started finasteride for hair loss with initial success but experienced increased shedding after 7 months. They are considering oral minoxidil as advised by their doctor to address the worsening hair loss.

Oral dutasteride and oral minoxidil are recommended for hair regrowth, with topical treatments being less effective. Stopping treatment results in losing any regrowth achieved.

Users discussed experiences with Everychem's solution similar to PP405 for hair loss, noting some positive results like increased hair thickness and new growth. There was skepticism about the product's legitimacy and safety, with some users reporting early signs of effectiveness and others expressing concerns about the lack of evidence and safety profiles.

Dutasteride may affect semen parameters but not significantly enough to impact fertility unless baseline fertility is already low. Finasteride and minoxidil are used for hair regrowth, with no side effects reported by one user.

A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.

RU58841 and Pyrilutamide (Kx-826) are both topical anti-androgens, but neither is effective for hair regrowth. RU58841 has more anecdotal support, while Pyrilutamide has progressed further in trials, though both have limitations.

Finasteride improved scalp hair but thinned beards for some users. Some suggest trying minoxidil on the beard, though results vary.

A 17-year-old is experiencing hair loss despite using 5% topical minoxidil, 0.05% tretinoin, and oral minoxidil, and is considering starting oral finasteride after a dermatologist suggested a hair growth spray with Capixyl, Redensyl, Anagain, and Saw Palmetto. Users advise caution with finasteride at a young age, suggesting starting with topical finasteride and consulting an endocrinologist.

Finasteride and dutasteride are discussed as preventative treatments for hair loss, with some advocating for early use and others concerned about side effects, especially before full maturity. Many regret not starting these treatments earlier due to their effectiveness in preventing or slowing hair loss.

An 18-year-old with diffuse hair thinning is considering switching from a topical Minoxidil 10% + Finasteride 0.1% solution to Minoxidil 5% foam and oral Finasteride 0.5mg, while also addressing vitamin D deficiency and potential scalp inflammation. Users suggest using Nizoral shampoo for inflammation, considering dutasteride for better results, and maintaining vitamin D levels to protect hair follicles from DHT.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

A user is seeking hair loss treatments without using systemic DHT blockers like finasteride due to side effects. Suggestions include clascoterone (not FDA approved), pyrilutamide, RU58841, and low-dose topical finasteride, with a recommendation to consult a doctor.

GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.

A user claims a product can treat alopecia, but others are skeptical, calling it a scam due to lack of evidence and transparency. The product is said to inhibit Type II 5-αr by 22.9%, but is considered weaker than existing DHT blockers.

A 20-year-old male using 1mg finasteride daily and 5% minoxidil twice a day for two months reported significant hair regrowth with no side effects. Users discussed the effectiveness of these treatments, the importance of consulting a doctor, and the potential for continued improvement over time.

The user stopped using finasteride due to side effects and is considering Fluridil (Eucapil) as an alternative for hair loss treatment. They are exploring other options like RU58841 and are interested in the experiences of others with Fluridil, noting its good safety profile despite the cost.

Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

The user experienced positive scalp results with Dutasteride but noticed beard thinning, prompting a switch back to Finasteride. They plan to monitor the situation and may consider combining treatments in the future.

A 24-year-old male shared his 5.5-year progress using minoxidil and nearly 5 years on finasteride/dutasteride for hair loss, reporting no side effects and successful results. He uses 0.5 mg dutasteride daily, oral minoxidil 2.5 mg daily, and topical minoxidil daily, with costs around $4 monthly.

The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.

A person has been using 1mg Finasteride for 20 years with no side effects but is now noticing temple thinning and is considering oral Minoxidil, despite concerns about heart health and body hair growth. They are consulting a doctor about possibly taking 1.25 to 2.5 mg of oral Minoxidil.

A 17-year-old is experiencing early hair thinning and is considering oral minoxidil while being cautious about finasteride due to side effects. They seek advice on hair maintenance and plan to consult a doctor before using DHT blockers.

A 16-year-old is experiencing hair loss and feels self-conscious. They are using rosemary oil daily but have not started minoxidil or finasteride.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

A 17-year-old male is experiencing genetic hair thinning and is considering using finasteride and minoxidil for treatment. He is frustrated with dermatologists' suggestions of vitamins and seeks advice on effective solutions.

CRISPR Cas9 could potentially treat baldness by targeting specific genes in hair follicles without affecting other body functions. There is optimism about its future use, despite ethical concerns and the current reliance on treatments like minoxidil and finasteride.

A new hair loss treatment, pp405, may regrow hair better than finasteride and minoxidil, with potential availability by 2028. However, there is skepticism about its effectiveness and commercialization timeline.

The user started using finasteride daily and ketoconazole occasionally, noticing reduced hair fall but no regrowth. Others shared mixed experiences with finasteride, some considering switching to dutasteride or adding minoxidil.

The user experienced decreased libido with saw palmetto and is now considering topical anti-androgens like RU58841, pyrilutamide, and topical dutasteride for hair loss. Minoxidil is also mentioned as a potential addition, but the user is cautious about side effects and availability of treatments.